Printer Friendly

R.P. SCHERER SIGNS AGREEMENT WITH PIERRE FABRE

 R.P. SCHERER SIGNS AGREEMENT WITH PIERRE FABRE
 TROY, Mich., March 16 /PRNewswire/ -- R.P. Scherer Corporation


(NYSE: SHR) and the French pharmaceutical company, Pierre Fabre Medicaments, announced today that they have entered into a number of agreements relating to the development, manufacture and supply of products incorporating a number of drugs in Scherer's Scherersol(R) softgel systems.
 The agreements allow Pierre Fabre to select up to eight compounds for exclusive worldwide development and marketing in softgel formulations incorporating Scherer's proprietary Scherersol systems. These Scherersol systems are patented softgel formulation technologies which are designed to improve the bioavailability of drugs that are inconsistently, incompletely or too slowly absorbed from traditional oral dosage forms.
 Pierre Fabre is the second-largest privately owned French pharmaceutical company and had annual sales of 4.1 billion French francs ($750 million) in 1991. Sales are expected to exceed 5 billion French francs ($880 million) in 1992. The company employs 5,300 people.
 R.P. Scherer Corporation, a leading international developer and manufacturer of drug delivery systems, is the world's largest producer of soft gelatin capsules ("softgels"). The company is also currently developing and commercializing advanced drug delivery systems, including the Scherersol(R), Zydis(R) and Pulsincap(TM) technologies. The company's proprietary drug delivery systems improve the efficacy of drugs by regulating their dosage, rate of absorption and place of release. The company operates a global network of 15 facilities in 11 countries.
 -0- 3/16/92
 /CONTACT: Alex Erdeljan of R.P. Scherer Corporation, 313-649-0900/
 (SHR) CO: R.P. Scherer Corporation ST: Michigan IN: MTC SU: LIC


KK -- DE016 -- 8275 03/16/92 11:27 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 16, 1992
Words:270
Previous Article:ENEX RESOURCES CORPORATION REPORTS INCREASED OIL AND GAS RESERVES
Next Article:AGENCE FRANCE-PRESSE ANNOUNCES AGREEMENT WITH PRESSLINK
Topics:


Related Articles
R.P. SCHERER ANNOUNCES AGREEMENT TO SELL PACO TERMINATED
SCHERER ANNOUNCES ZYDIS PRODUCT LAUNCH IN ITALY
SCHERER ANNOUNCES LAUNCH OF ANOTHER PRODUCT UTILIZING ITS ZYDIS TECHNOLOGY
R.P. SCHERER ANNOUNCES PULSINCAP(R) RESEARCH AGREEMENT
ZENECA AND R.P. SCHERER SIGN LICENSE AGREEMENT
SCHERER OBTAINS RIGHTS TO NEW DRUG DELIVERY SYSTEMS
SANDOZ AND R.P. SCHERER RENEW COLLABORATIVE AGREEMENT
R. P. Scherer and Merck Enter Into Global Softgel Development Agreement
Scherer And Glaxo Sign Agreements
R.P. Scherer Announces Agreement with GlaxoWellcome.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters